ATE534375T1 - Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid - Google Patents
Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamidInfo
- Publication number
- ATE534375T1 ATE534375T1 AT09768977T AT09768977T ATE534375T1 AT E534375 T1 ATE534375 T1 AT E534375T1 AT 09768977 T AT09768977 T AT 09768977T AT 09768977 T AT09768977 T AT 09768977T AT E534375 T1 ATE534375 T1 AT E534375T1
- Authority
- AT
- Austria
- Prior art keywords
- indol
- diethylamino
- pyrrole
- dihydro
- oxo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08011444A EP2138167A1 (de) | 2008-06-24 | 2008-06-24 | Pharmazeutische Zusammensetzung mit N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyrrol-3-Carboxamid |
PCT/EP2009/004529 WO2009156128A1 (en) | 2008-06-24 | 2009-06-23 | Pharmaceutical composition comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1 h-pyrrole-3-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE534375T1 true ATE534375T1 (de) | 2011-12-15 |
Family
ID=39884239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT09768977T ATE534375T1 (de) | 2008-06-24 | 2009-06-23 | Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid |
Country Status (7)
Country | Link |
---|---|
EP (2) | EP2138167A1 (de) |
KR (1) | KR101629526B1 (de) |
AT (1) | ATE534375T1 (de) |
CA (1) | CA2728852C (de) |
ES (1) | ES2377286T3 (de) |
IL (1) | IL210141A (de) |
WO (1) | WO2009156128A1 (de) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3539536A1 (de) * | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | Pharmazeutische zusammensetzung von sunitinib oder salz davon in seiner polymorphen form i |
WO2020091439A1 (ko) * | 2018-10-31 | 2020-05-07 | 주식회사 삼양바이오팜 | 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법 |
KR102308227B1 (ko) * | 2018-10-31 | 2021-10-05 | 주식회사 삼양홀딩스 | 수니티닙을 함유하는 경구용 정제 조성물 |
KR102322429B1 (ko) * | 2018-10-31 | 2021-11-08 | 주식회사 삼양홀딩스 | 수니티닙을 함유하는 경구용 제제 및 그의 제조 방법 |
WO2021125788A1 (ko) * | 2019-12-17 | 2021-06-24 | 주식회사 삼양홀딩스 | 수니티닙 염산염을 포함하는 경구용 고형제제 및 그 제조 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1928501A (en) * | 1999-11-24 | 2001-06-04 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
NZ519697A (en) | 1999-12-22 | 2004-08-27 | Sugen Inc | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
CZ303705B6 (cs) | 2000-02-15 | 2013-03-27 | Sugen, Inc. | Pyrrolem substituovaná 2-indolinonová sloucenina pro pouzití jako inhibitor proteinkináz a farmaceutická kompozice s jejím obsahem |
CN100439360C (zh) | 2001-08-15 | 2008-12-03 | 法玛西雅厄普约翰美国公司 | 包括n-[2-(二乙氨基)乙基]-5-[(5-氟-2-氧代-3h-吲哚-3-亚基)甲基]-2,4-二甲基-1h-吡咯-3-甲酰胺的苹果酸盐的晶体、其制备方法和其组合物 |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
TW200418836A (en) | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
-
2008
- 2008-06-24 EP EP08011444A patent/EP2138167A1/de not_active Withdrawn
-
2009
- 2009-06-23 ES ES09768977T patent/ES2377286T3/es active Active
- 2009-06-23 CA CA2728852A patent/CA2728852C/en active Active
- 2009-06-23 AT AT09768977T patent/ATE534375T1/de active
- 2009-06-23 EP EP09768977A patent/EP2306990B1/de active Active
- 2009-06-23 KR KR1020117001608A patent/KR101629526B1/ko active IP Right Grant
- 2009-06-23 WO PCT/EP2009/004529 patent/WO2009156128A1/en active Application Filing
-
2010
- 2010-12-21 IL IL210141A patent/IL210141A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2138167A1 (de) | 2009-12-30 |
EP2306990A1 (de) | 2011-04-13 |
ES2377286T3 (es) | 2012-03-26 |
EP2306990B1 (de) | 2011-11-23 |
KR101629526B1 (ko) | 2016-06-10 |
IL210141A0 (en) | 2011-03-31 |
CA2728852A1 (en) | 2009-12-30 |
CA2728852C (en) | 2016-07-26 |
WO2009156128A1 (en) | 2009-12-30 |
IL210141A (en) | 2013-05-30 |
KR20110022690A (ko) | 2011-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0923728A2 (pt) | "método de preparação de compostos de di-hidroindeno amida, suas composições farmacêuticas contendo esses compostos e uso como inibidor de proteína quinase". | |
WO2009109388A8 (en) | Crystal forms of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide and methods for their preparation | |
BRPI0922073A2 (pt) | Compostos de éter com heterociclo de 5 membros contendo nitrogênio e usos dos mesmos. | |
UY29575A1 (es) | Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico | |
CY1116118T1 (el) | Κρυσταλλικες μορφες (r)-5-[3-χλωρο-4-(2,3-διυδροξυ-προποξυ)-βενζ[ζ]υλιδενιο]-2-([ζ]-προπυλιμινο)-3-o-τομυλ-θειαζολιδιν-4-ονης | |
BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
DOP2013000078A (es) | Compuesto derivado de heterociclos nitrogenados sustituidos, eficaz como inhibidor de la replicación del virus de la hepatitis c, composición que lo comprende y su uso | |
CO6311084A2 (es) | Combinaciones de compuestos activos que tienen propiedades insecticidas y acaricidas | |
SI3168218T1 (sl) | Kristal, ki vključuje sol L-jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, za uporabo kot zdravilo | |
DK2139494T3 (da) | Farmaceutiske formuleringer, der indeholder dapagliflozin-propylenglycolhydrat | |
CL2013002241A1 (es) | Compuestos derivados de (4,4´-bifeniilbis(1h-imidazol-4,2-diil)-2,1-pirrolidindiil((1s)-1-((2r,6r)-2,4-dimetilltetrahidro-2h-piran-4-il)-2-oxo-2,1-etandiil)))biscarbamato de dimetilo, inhibidores del vhc; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso para tratar una infeccion por vhc. | |
DK2254549T3 (da) | Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser | |
ATE527244T1 (de) | N-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2- yl)benzyl-n'-arylcarbonylpiperazinderivate als lxr modulatoren | |
ITCO20080005A1 (it) | "shaker monouso" | |
NO20090797L (no) | Farmasoytiske blandinger omfattende kandesartan cileksetil | |
ATE534375T1 (de) | Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid | |
EA201001857A1 (ru) | Фармацевтическая лекарственная форма для немедленного высвобождения производного индолинона | |
EA200970532A1 (ru) | Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола | |
BRPI0814891A2 (pt) | Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo. | |
SE0800742L (sv) | Vikttäcke | |
EA201001125A1 (ru) | Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид | |
EA201071309A1 (ru) | Твердая фармацевтическая композиция | |
IL209815A0 (en) | Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use | |
ATE537822T1 (de) | Antidepressivum | |
EA201100104A1 (ru) | Фармацевтическая композиция, содержащая статин |